Potential usefulness of CTC detection in follow up of prostate cancer patients. A preliminary report obtained by using Adnagene platform

Archivio Italiano di Urologia e Andrologia

Volumn 85, Issue 4, 2013, Pages 164-169

  Albino, Giuseppe ^a,b   Vendittelli, Francesca ^a   Paolillo, Carmela ^a   Zuppi, Cecilia ^a   Capoluongo, Ettore ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Ospedale di Andria   (Italy)

Author keywords

AdnaTest; Circulating prostate tumor cells; Prostate cancer

Indexed keywords

BICALUTAMIDE; DOCETAXEL; LEUPRORELIN; MESSENGER RNA; MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN; TRIPTORELIN; ZOLEDRONIC ACID;

ANTIANDROGEN THERAPY; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HUMAN CELL; LOW RISK POPULATION; LYMPH NODE DISSECTION; MALE; PATIENT IDENTIFICATION; PROSTATE CANCER; PROSTATECTOMY; TREATMENT FAILURE;

FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS;

EID: 84892681826     PISSN: 11243562     EISSN: 22824197     Source Type: Journal    
DOI: 10.4081/aiua.2013.4.164     Document Type: Article

References (40)

1. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on Prostate Cancer Eur Urol. 2011; 59:61-71 and 59:572-83.
2. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995; 332:1393-8.
3. Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009, 56:594-605.
4. Kruck S, Gakis G, Stenzl A. Circulating and disseminated tumor cells in the management of advanced prostate cancer. Adv Urol. 2012;135281. Epub 2011 Aug 21.
5. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007; 253:180-204.
6. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008; 8:329-40.
7. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Clin Cancer Res. 2004; 10:6897-904.
8. Jost M, Day JR, Slaughter R, et al. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer. 2010; 2:174.
9. Moreno JG, Croce CM, Fischer R, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 1992; 52:6110-12.
10. Katz AE, Olsson CA, Raffo AJ, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology. 1994; 43:765-75.
11. Sokoloff MH, Tso CL, Kaboo R, et al. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol 1996; 156:1560-66.
12. Thiounn N, Saporta F, Flam TA, et al. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology. 1997; 50:245-50.
13. Smalla AC, Gonga Y, Oh WK, et al. The Emerging Role of Circulating Tumor Cell Detection in Genitourinary Cancer. J Urol. 2012; 188:21-6.
14. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450:1235-9.
15. Ellis WJ, Pfitzenmaier J, Colli J, et al. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology. 2003; 61:277-81.
16. Moreno JG, Miller MC, Gross S, et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005; 65:713-18.
17. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13:7053-58.
18. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration resistant prostate cancer. Clin Cancer Res. 2008; 14:6302-09.
19. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10:233-9.
20. Stott SL, Lee RJ, Nagrath S, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010; 2:25ra23.
21. Rosenberg R, Gertler R, Friederichs J, et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 2002;49:150-58.
22. Todenhöfer T, Hennenlotter J, Feyerabend S, et al. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res. 2012; 32:3507-13.
23. Reynolds MA. Molecular alterations in prostate cancer. Cancer Lett. 2008; 271:13-24.
24. Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer - the post PSA era. Anticancer Res. 2009; 29:3289-98.
25. D'Amico AV, Whittington R, Broderick GA. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998; 280:969-74.
26. Benoy IH, Elst H, Van Dam P, et al. Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. Clin Chem Lab Med. 2006; 44:1082-7.
27. Cohen SJ, Punt C J, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26:3213-21.
28. Torino F, Bonmassar E, Bonmassar L, et al. Circulating tumor cells in colorectal cancer patients. Treat Rev. 2013 Jan 30. doi:pii: S0305-7372(13)00002-9.10.1016/j.ctrv.2012.12.007.
29. Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journal of Cancer. 2011; 105:847-53.
30. Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis Clin. Cancer Res 2008; 14:5013-21.
31. Allan AL, Vantyghem SA, Tuck AB, et al. Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometry. Cytometry. 2005; 65:4-14.
32. Wiedswang G, Borgen E, Schirmer C, et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer. 2006; 118:2013-19.
33. Wong NS, Kahn HJ, Zhang L, et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat. 2006; 99:63-9.
34. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol. 2002; 20:3404-12.
35. Benoy IH, Elst H, Van der Auwera I, et al. Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer. 2004; 91:1813-20.
36. Doyen J, Alix-Panabièresd C, Hofmanb P, et al. Circulating tumor cells in prostate cancer: A potential surrogate marker of survival. Crit Rev Oncol Hematol. 2012; 81:241-56.
37. Perner S, Hofer KR, Shah RB, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007; 38:696-701.
38. Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res. 1994; 54:1807-11.
39. th edn. Wiley-Blackwell. 2009; pp. 243-248.
40. Andreopoulou E, Yang LY, Rangel KM, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer. 2012; 130:1590-7.